Synthesis and immunological evaluation of TLR1/2 ligand-conjugated RBDs as self-adjuvanting vaccine candidates against SARS-CoV-2

Yoshiyuki Manabe, Brandon Gárate-Reyes, Keita Ito, Ramón Hurtado-Guerrero, Kazuya Kabayama, Koichi Fukase. Chem Commun (Camb). 2024 Mar 18. PMID: 38497901 DOI: 10.1039/d4cc00462k

We synthesized and evaluated Pam3CSK4-conjugated receptor binding domain (RBD)/deglycosylated RBD as potential anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates. Our investigation revealed the critical importance of limiting the number of introduced Pam3CSK4 molecules to the RBD in order to preserve its antigenicity. We also confirmed the harmonious integration of the adjuvant-conjugation strategy with the glycan-shield removal strategy.

Impact factor: